TRAF4 identification as a new direct target of miR-29s reveals that higher TRAF4 levels increase CLL response to CD40 activation and downstream nuclear factor-κB (NF-κB) signaling. Here, NFKB1 is linked to B-cell chronic lymphocytic leukemia.